Physician profile
Ananth Thyagarajan
NPI 1356516546
$97,202.33
in general payments reported to CMS, 2019-2025
23 companies · $4,744 in 2025
The $4,744 reported for 2025 was more than what 83% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $14K · 2021: $27K · 2022: $19K · 2023: $17K · 2024: $16K · 2025: $4,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Consulting Fee: $5,769 · Travel and Lodging: $3,819 · Food and Beverage: $2,395 · Honoraria: $175 · Education: $67.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,405.00 |
| Consulting Fee | $5,769.25 |
| Travel and Lodging | $3,818.52 |
| Food and Beverage | $2,395.35 |
| Honoraria | $175.00 |
| Education | $67.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $37,151.61 | 2020-2023 | |
| Astrazeneca Pharmaceuticals Lp | $28,437.13 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Kaleo, INC. | $7,333.06 | 2019-2024 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $6,756.09 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $6,022.76 | 2019-2025 | |
| Genzyme Corporation | $2,775.10 | 2019-2025 | |
| Alk-Abello, INC | $2,335.11 | 2021-2022 | |
| Amgen INC. | $2,137.12 | 2022-2025 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $2,085.09 | 2025 | Neffy |
| Abbvie INC. | $827.32 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $297.11 | 2020-2023 | Dupixent |
| Glaxosmithkline, LLC. | $247.51 | 2019-2024 | Nucala |
| Optinose US, INC. | $235.50 | 2021 | |
| Incyte Corporation | $94.69 | 2021-2023 | Opzelura |
| Genentech USA, INC. | $82.63 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $81.21 | 2021 | |
| Biocryst US Sales Co., LLC | $70.20 | 2021 | |
| Csl Behring | $65.16 | 2019 | |
| Greer Laboratories, INC. | $59.59 | 2024 | Palforzia |
| Blueprint Medicines Corporation | $36.61 | 2023 | Ayvakit |
| Nestle Healthcare Nutrition INC. | $28.24 | 2021 | |
| Sanofi-Aventis U.S. LLC | $26.39 | 2021 | |
| Merck Sharp & Dohme LLC | $17.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ananth Thyagarajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.